Solstein Capital’s Boston Scientific BSX Stock Holding History

Solstein Capital’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-133	Closed	-$12.7K	–	457
2025 Q4	$12.7K	Hold	133	–	–	0.01%	312
2025 Q3	$13K	Sell	133 -229	-63%	-$23.7K	﹤0.01%	314
2025 Q2	$38.9K	Buy	+362	New	+$36.6K	0.02%	220
2020 Q2	–	Sell	-269	Closed	-$9K	–	222
2020 Q1	$9K	Buy	269 +36	+15%	+$1.41K	0.03%	193
2019 Q4	$11K	Buy	+233	New	+$9.75K	0.02%	250

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Solstein Capital's BSX Position: Q1 2026 in Review

Solstein Capital sold out of Boston Scientific (BSX) in Q1 2026, closing a stake of 133 shares — an estimated $12.7K sold.

Solstein Capital first reported a position in BSX in Q4 2019 and held it in 5 quarters. The position peaked at $38.9K in Q2 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

Solstein Capital reported no remaining Boston Scientific position as of Q1 2026 after selling out during the quarter.
Solstein Capital sold 133 Boston Scientific shares in Q1 2026, an estimated $12.7K.
Solstein Capital first reported a position in Boston Scientific in Q4 2019 and held it in 5 quarters.
Solstein Capital's Boston Scientific position peaked at $38.9K in Q2 2025.
1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Solstein Capital's 13F filing for Q1 2026, filed 14 May 2026.